deltatrials
Active Not Recruiting OBSERVATIONAL NCT05582902

Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients (PRO-RED)

Longitudinal, App-based Assessment of Varying Red Blood Cell Transfusion Strategies and Their Association With Patient-Reported, Clinical and Economical Outcomes in Lower-risk Myelodysplastic Neoplasms (MDS) Patients

Sponsor: Deutsche Krebshilfe e.V., Bonn (Germany)

Conditions MDS MDS/MPN
Updated 12 times since 2022 Last updated: Apr 9, 2026 Started: Oct 11, 2022 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on MDS and MDS/MPN, this trial is ongoing. The trial is conducted by Deutsche Krebshilfe e.V., Bonn (Germany) and has accumulated 12 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshotRecruiting~Mar 2023 – ~May 2023 · 2 months · monthly snapshotRecruiting~May 2023 – ~Jul 2023 · 2 months · monthly snapshotRecruiting~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshotRecruiting~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshotRecruiting~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshotRecruiting~Feb 2024 – ~May 2024 · 3 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotRecruiting~Jun 2025 – ~Apr 2026 · 10 months · monthly snapshotRecruitingApr 16, 2026 – present · 5 months · daily APIActive Not Recruiting

Change History

12 versions recorded
  1. Apr 16, 2026 — Present [daily]

    Active Not Recruiting

    Status: RecruitingActive Not Recruiting

  2. Jun 2025 — Apr 2026 [monthly]

    Recruiting

  3. Sep 2024 — Jun 2025 [monthly]

    Recruiting

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting

  5. May 2024 — Jul 2024 [monthly]

    Recruiting

Show 7 earlier versions
  1. Feb 2024 — May 2024 [monthly]

    Recruiting

  2. Jan 2024 — Feb 2024 [monthly]

    Recruiting

  3. Aug 2023 — Jan 2024 [monthly]

    Recruiting

  4. Jul 2023 — Aug 2023 [monthly]

    Recruiting

  5. May 2023 — Jul 2023 [monthly]

    Recruiting

  6. Mar 2023 — May 2023 [monthly]

    Recruiting

  7. Nov 2022 — Mar 2023 [monthly]

    Recruiting

    First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

PRO-RED is a prospective, longitudinal, and multicenter observational study. Enrolled patients will be followed for 6 months in at least monthly intervals in terms of their received red blood cell transfusions and routine myelodysplastic neoplasms (MDS)-associated clinical parameters. In addition, the participating subjects will be provided with a digital/mobile application covering a smartphone app or paper-based questionnaires to answer a set of quality of life (QoL) questions once a week. During routine visits in the clinical trials center performed by the treating physician (at least every month), patients will answer standardized questionnaires for the assessment of MDS-related QoL. Also, included patients will take a photo of fingernails/eyelids with their smartphone camera with the aim to further analyze these pictures in a way to potentially deduct correlated hemoglobin (Hb)-values. As a long term aim beyond the PRO-RED study, the data will serve as a training cohort for the development of an algorithm for image-based calculation of individual Hb levels.

Contact Information

Sponsor contact:
  • Deutsche Krebshilfe e.V., Bonn (Germany)
  • University of Leipzig
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .